Silence Therapeutics moves siRNA drug for polycythemia vera to Phase 3 after Phase 2 success
Silence Therapeutics announced that its siRNA candidate divesiran achieved its primary endpoint in a Phase 2 study in patients with polycythemia vera, a rare blood cancer.
The trial results showed the drug reduced key disease markers and was well tolerated, meeting the pre-specified efficacy criteria.
Based on the data, the company plans to initiate a pivotal Phase 3 program later this year, aiming for broader enrollment and regulatory filing.
The advancement highlights the potential of gene-silencing approaches for hematologic disorders and may attract further interest from investors and partners.
This writeup was produced by pharmadog from original reporting by Endpoints.
Original headline: “Silence spells out Phase 2 success for gene-silencing drug in rare blood cancer”
read at Endpoints ↗
comments(0)
5-min edit window · permanent after that